HC Wainwright reiterated their buy rating on shares of BELLUS Health (NASDAQ:BLU – Get Rating) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright also issued estimates for BELLUS Health’s Q1 2023 earnings at ($0.20) EPS, Q2 2023 earnings at ($0.21) […]